Vonoprazan is a potassium-competitive acid blocker, with acid suppressing activity. Upon oral administration, vonoprazan concentrates in the gastric parietal cells and competitively and reversibly binds to the potassium binding site of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump’s activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. Its therapeutic use is listed as gastrointestinal agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Vocinti and Takecab. Its PubChem CID is 15981397.
Vonoprazan
| CAS No | 881681-00-1 |
|---|---|
| Molecular Formula | C17H16FN3O2S |
| Molecular Weight | 345.4 g/mol |
| Synonyms | 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Vonoprazan is a potassium-competitive acid blocker, with acid suppressing activity.
The listed CAS number is 881681-00-1.
The listed molecular formula is C17H16FN3O2S.
The listed molecular weight is 345.4 g/mol.
1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine.
The source lists Vocinti and Takecab.